A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 [abatacept] in Subjects With Active Rheumatoid Arthritis on Background DMARDS Who Have Failed Anti-TNF Therapy.

Trial Profile

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 [abatacept] in Subjects With Active Rheumatoid Arthritis on Background DMARDS Who Have Failed Anti-TNF Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs Abatacept (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTAIN
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Jun 2016 Results a post hoc analysis from AIM and ATTAIN and AGREE (n=1536) presented at the 17th Annual Congress of the European League Against Rheumatism
    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top